Globus Medical stock gained 1.28 percent as Zacks ranked GMED first at 76.57 USD
Published on 10/07/2026 at 02:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Globus Medical stock (ISIN US3795772082) gained 1.28 percent to USD 76.57 on the NYSE on October 6, 2026. Zacks listed GMED at Rank #1, or Strong Buy, in its October 6, 2026 industry outlook. The stock remains 24.49 percent below its 52-week high of USD 101.40.
Q2 revenue reached USD 789.61 million
Globus Medical reported USD 789.61 million in Q2 2026 revenue, up 5.9 percent from the prior-year quarter, according to MarketBeat. Reported earnings per share came to USD 1.34, compared with a USD 1.10 consensus estimate, while the company set fiscal 2026 EPS guidance at USD 4.950-5.050.
The earnings mix gives the stock a measurable operating base for the current debate. Revenue growth was positive, but the latest quarterly net margin cited by MarketBeat was 17.02 percent, leaving profitability as an important counterweight to the sales increase.
Consensus target stays above the stock
MarketBeat reported on September 29, 2026, that 17 analysts held a Moderate Buy consensus, comprising nine Buy ratings, three Strong Buy ratings and five Hold ratings. The average 12-month target was USD 101.77, which placed the target 32.82 percent above the October 6 closing price of USD 76.57.
The analyst picture is not uniformly bullish. Markets Insider reported on October 1, 2026, that RBC Capital lowered its target from USD 115 to USD 85 while retaining an Outperform rating. RBC cited second-half caution in two business areas and volatility in spine markets.
Excelsius3D expands the product platform
The company also has a concrete product milestone behind its longer-term strategy. ORTHOWORLD reported on September 8, 2026, that Excelsius3D received CE Mark approval for commercial sale in the European Union and the United Kingdom.
The system combines 3D cone-beam computed tomography, 2D fluoroscopy and digital radiography, and can operate with the ExcelsiusGPS robotic navigation platform. That expands the addressable use of Globus Medical's enabling-technology ecosystem, while the RBC target reduction shows that execution and spine demand remain central to valuation.
Globus Medical stock closes above USD 76
Globus Medical stock closed at USD 76.57 on October 6, 2026, on the NYSE, with volume of 1,606,796 shares. The daily range was USD 75.03 to USD 77.17, and the market capitalization was USD 10.3 billion.
Globus Medical stock facts
- Company: Globus Medical, Inc.
- ISIN: US3795772082
- Ticker: GMED
- Trading venue: NYSE
- Price (as of October 6, 2026): USD 76.57 Closing price
- Market capitalization: USD 10.3 billion (as of October 6, 2026)
- 52-week range: USD 56.50-101.40 (as of October 6, 2026)
- Sector / Industry: Healthcare / Medical Devices
